Mastitis is considered to be the most costly disease affecting the dairy industry. Management strategies involve the extensive use of antibiotics to treat and prevent this disease. Prophylactic dosages of antibiotics used in mastitis control programmes could select for strains with resistance to antibiotics. In addition, a strong drive towards reducing antibiotic residues in animal food products has lead to research in finding alternative antimicrobial agents.
Bacteriocins alternatives in mastitis treatment endotoxemia occurs (65, 67) .
Nocardia asteroides causes severe cases of mastitis resulting in fibrosis and permanent damage to mammary tissues (67) . Treatment is usually ineffective and a high mortality rate occurs. The source of the infection caused by Nocardia asteroides is usually from the soil and could be prevented by ensuring that effective sanitation measures are enforced before treatment with intramammary infusions (65) .
Less common causes of bovine mastitis include Bacillus cereus, resulting in peracute and acute mastitis and also the human pathogens Streptococcus pyogenes and S. pneumonia that causes acute mastitis and is accompanied by fever symptoms in the host (67) .
Current aetiology of mastitis
Contagious organisms have usually been responsible for the highest incidence of both clinical and sub-clinical cases of mastitis. Bradley (8) E. coli and Enterobacteriacae, however, were responsible for 34.7 % and 40.9 %, respectively, of all cases (9) .
Adequate mastitis control strategies have thus played a key role in reducing contagious cases of mastitis. It would appear however, that as contagious pathogens were reduced, opportunistic and environmental pathogens seemed to play a greater role in causing persistent infections (8) . The importance of the correct diagnosis and identification of the aetiological agent causing inflammation in the udder tissue is essential in determining the treatment strategies. It is also important to understand the history of mastitis incidence within a herd over a period of time and to understand the different periods when a cow may be at higher risk for infection. For example, cows are especially susceptible to mastitis during the periparturient period (just before and after calving) and at drying off -due to structural changes occurring in the mammary gland. A decrease in the number and functionality of white blood cells caused by interactions with specific hormones during these periods results in a compromised defence system (61, 95) .
Infection
Mammary structure is composed of the milk-producing tissue or alveoli that lead into the lactiferous ducts, gland cistern, teat canal and finally the teat opening or duct. The alveoli are lined with epithelial cells that become specialised during the gestation period, before calving, and after calving.
These specialised cells produce colostral and lacteal secretions and finally, milk. Connective tissue and muscle cells support the alveoli glands and contract and squeeze milk from the alveoli during milking (29, 65) . (2) , S. dysgalactiae (3) and E. coli (21, 22) adhere to and internalise into epithelium cells. Persistence of the pathogen in the tissue may vary, some are easily destroyed by the host immune system while others such as S. aureus are well-adapted and cause serious injury within the mammary tissue, producing virulence factors that disarm the host immune systems cells (2, 36) .
E. coli and other coliform pathogens are not only able to adhere to and invade epithelium (22) but are also able to multiply rapidly in the gland cistern, which elicits a rapid inflammatory response that destroys a large number of the invading pathogens. However, upon cell lyses endotoxins are released causing severe toxaemia in the blood stream of the cow (65, 67) .
Mastitis control strategies
The "five point plan for mastitis control" has been the gold Bacteriocins alternatives in mastitis treatment standard for control strategies for many years (29) , and has been successful in reducing the incidence of mastitis. The strategy addresses areas where the risk of infection is the greatest and promotes the use of treatment at specific times. Welfare Council in the UK has defined "the five freedoms" of animals, which highlight issues relating to the treatment and management of animals. The advantage of implementing such quality control measures within the herd would ensure that dairy cows are free of a stressful environment, injury, pain, hunger and discomfort, which in turn would promote a healthy immune system and udder health in general (77) .
The milking practice is of paramount importance as this is most often the route of infection. The udder should be prepared before milking by washing the teats, followed by disinfection and drying with clean paper towels. If the teat area is dripping with water from run-off of areas that were heavily soiled it could lead to pathogens gaining access to the teat canal. Milker's hands should also be disinfected to prevent the transfer of pathogens. Post milking treatment is also important and all cows should be treated with a teat dip disinfectant to reduce the risk of infection (29, 65) .
Monitoring SCC on a regular basis and follow-up investigations give an indication of the success of good animal husbandry and hygiene practices. It therefore forms an integral part of mastitis control strategies and assists in diagnosis and treatment.
The elimination of mastitis in a herd may require the culling of cows that are incurable or are so severely infected that the mammary tissue has been scarred and damaged to the extent that the tissue no longer functions (29) .
Treatment
A cow may spontaneously recover from mastitis, but this will usually occur in mild cases of subclinical mastitis.
Theoretically, the mechanism by which a cow recovers from infection without treatment can be capitalised upon to produce a vaccine (65 The teat sealant is composed of an inert salt (bismuth subnitrate) in a paraffin base. The paste is infused into the teat of each quarter using a sterile syringe. After drying-off, the product is stripped out at first milking (64) . To ensure that other pathogens are not introduced into the teat along with the teat sealant, trained personnel should perform the administration of the product. 
Lactation therapy
The use of antimicrobials during lactation must be carefully considered. Only cases of clinical mastitis and some specific cases of subclinical mastitis, where the quality and production of the milk is severely affected, are treated.
Mastitis caused by S. agalactiae can be treated most readily during lactation and has a high cure rate (90-95 %) . Mastitis caused by S. aureus has the lowest cure rate and along with environmental streptococci should be treated during the dry period (65) .
An important consideration for treatment during lactation is the presence of antibiotic residues in the milk. A waiting period is required for the duration of the treatment and for a given period after treatment where milk and meat products need to be withheld to ensure that the level of antibiotics present in the product meets the legislative requirements. The withdrawal period and the type of product that is administered vary in different countries (34) . The cost of treatment and the loss of milk during the withdrawal period are important in determining the type of product used and the manner in which it is administered. The withdrawal period for milk products marketed during lactation varies between 1 and 4 days ( Table   3 ). A product is considered excellent if it has a high cure rate and a minimum withdrawal period (34) .
Efficacy of drug delivery
The administration of drugs can be done either directly into the teat canal, as previously described for dry cow therapy, in the form of intramammary infusions, but can also be given parenterally by intravenous or intramuscular injection (65) .
The route of choice for subclinical mastitis is usually by intramammary infusion; and in the case of severe acute clinical mastitis, a combination of parenteral and intramammary treatment is usually necessary (104).
To be effective, the drug has to exert specific antimicrobial activity at the site of infection (34) 
Types of antimicrobial agents
Commonly used remedies available for dry cow and lactation therapy, the recommended withdrawal period and the possible activity spectrum of mastitis pathogens (24) are shown in Table 2 Polymixin B is an antimicrobial compound that binds to the cell membrane and disrupts its structure and permeability properties. It is the antimicrobial drug of choice for infections caused by P. aeruginosa (24) .
Macrolide antibiotics (tylosin, lincomysin, erythromycin)
are effective in treating Gram-positive udder infections both by parenteral and intramammary administration (24) . They are bacteriostatic and thus act in conjunction with the host immune system to fight infection. The mechanism of action is to inhibit protein synthesis by binding to the 50S ribosomal sub-unit to Bacteriocins alternatives in mastitis treatment prevent peptide elongation (66) .
What are the alternatives?
The risks involved in the treatment of mastitis has been discussed in terms of the development of antibiotic resistance, but from a commercial standpoint, milk products containing specific levels of antibiotic residues cannot be sold for human 
BACTERIOCINS -EXPLORING ALTERNATIVES TO ANTIBIOTIC TREATEMNT

INTRODUCTION
The study of the antibacterial properties of peptides that became known as colicins began in 1925 when one strain of E.
coli produced an antagonistic effect against another E. coli culture (33) . The antibiotic effect between other enteric bacteria was also reported by Fredericq and Levine (27) and further research into these proteinaceous molecules centred on colicins that were active against E. coli and various other Bacteriocins alternatives in mastitis treatment members of the family Enterbacteriaceae.
Colicin-like molecules produced by Gram-positive bacteria have also been studied extensively since the first report of nisin produced by L. lactis subsp. lactis (71) . The term "bacteriocin" was used to describe these antibiotic substances as not all were produced by coliform bacteria (42) and according to Tagg Commercial products are currently available for the treatment of mastitis in dairy cattle and will be discussed in more detail. 
Bacteriocins used in the treatment of mastitis
The most economically costly disease in cattle is mastitis.
As a result the dairy industry could benefit greatly from the development of safe antimicrobial agents and bacteriocins could be an attractive alternative to antibiotics. The treatment of mastitis has been a target of research since the inception of scientific research into the applications of bacteriocins (91).
To date, only the Lactococcal bacteriocin, nisin, has been developed for commercial application and the lantibiotic, lacticin 3147, has been extensively researched for dry cow therapy. Applications for prevention and treatment using these lactococcal bacteriocins will be discussed in detail below.
Other bacteriocins that are active against mastitis pathogens have also been investigated. Researchers have targeted staphylococci and streptococci isolated from the normal flora of the teat canal and other areas as these could be a source for bacteriocins to treat mastitis pathogens. The potential applications for these bacteriocins will also be discussed.
Lactococcal bacteriocins
Nisin: was the first bacteriocin applied to the preservation of food products and was approved for use in pasteurised Table 5 ). The formulation also showed little potential for skin irritation after repeated exposure in contrast to 1 % iodophore and 5 % chlorohexidine digluconate preparations. Table 6 shows the 
DPC3147 and was first isolated from Irish Keffir grain (74).
As with nisin, it is also classified as a Class 1a lantibiotic, but it differs from nisin in that it is a two-peptide lantibiotic, requiring both the LtnA1 and LtnA2 peptides for full activity.
The mode of action of lacticin 3147 is similar to that of nisin in that it results in the inhibition of cell synthesis and pore formation in the target cell (98) . When bound to the complex, LtnA2 is able to adopt a transmembrane conformation that results in the formation of a defined pore and the release of ions across the membrane (iii).
In an earlier study, McAuliffe et al. (53) reported that the pore formation resulted in the efflux of potassium ions and inorganic phosphate, resulting in the dissipation of the membrane potential and hydrolysis of internal ATP, the collapse of the pH gradient and cell death.
Lacticin 3147 has a broad spectrum of antimicrobial activity and inhibits the growth of Bacillus sp., Enterococcus sp., Lactobacillus sp., Pediococcus pentriceans, S. aureus, S.
thermophilus and most mastitis-causing streptococci. Foodborne spoilage bacteria, including L. monocytogenes and C.
tyrobutyricum, are sensitive to lacticin 3147 and the peptide could be used to prevent food spoilage and disease (74) .
Lacticin 3147 was investigated for use as an antimicrobial agent as it inhibited common mastitis-causing pathogens, including S. aureus, S. dysgalactiae, S. uberis and S. agalactiae (73) . The producing organism is GRAS and is active at both low and physiological pH and was heat stable (73, 74) .
Teat seal formulations such as Orbeseal ® (64) In separate studies, the bismuth subnitrate-based teat seal (Osmonds Teat Seal 2, Cross Vetpharm Group Ltd., Dublin, Ireland) combined with lacticin 3147 was evaluated against the mastitis-causing pathogens S. dysgalactiae (73) and S. aureus (16, 93) . Irritancy to the teat area and the somatic cell response were evaluated.
The protection given by the teat seal plus lacticin 3147 and the teat seal only were compared after experimental challenge with S. dysgalactiae. The results showed significant improvements in the level of protection afforded by the teat seal containing the bacteriocin 3147 (Table 7) . Ninety-one Bacteriocins alternatives in mastitis treatment (Table 8 ). The antagonistic effect of the bacteriocin at the same concentration was however reduced when the inoculum of the S. aureus challenge introduced into the teats was increased. The concentration of the bacteriocin used was found to be significant factor for the teat seal to be effective in reducing S. aureus in the teats. The method of drug delivery in a treatment strategy for mastitis is important and a teal seal offers many advantages.
Firstly it acts as a physical barrier and is prophylactic. By combining an antibacterial agent in a teat seal, the inhibitor is Bacteriocins produced by LAB are considered to be GRAS (generally regarded as safe) and would therefore be more acceptable when compared to antibiotics. Antibiotic therapy during lactation requires a withdrawal period, which results in economic losses due to wastage and loss of production time. Bacteriocin residues in milk are more acceptable as digestive enzymes easily destroy the peptides.
Thus, the withholding periods would be significantly reduced if bacteriocin therapy were used instead of antibiotic therapy.
Considering the extensive costs of a disease such as mastitis to the dairy industry, research directed towards viable and safe alternatives should be considered. Bacteriocins can thus be viewed as a real treatment solution to augment other management strategies and reduce the amount of antibiotics used in the treatment of mastitis.
